128 related articles for article (PubMed ID: 12639576)
1. Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors.
Sui Z; Guan J; Macielag MJ; Jiang W; Qiu Y; Kraft P; Bhattacharjee S; John TM; Craig E; Haynes-Johnson D; Clancy J
Bioorg Med Chem Lett; 2003 Feb; 13(4):761-5. PubMed ID: 12639576
[TBL] [Abstract][Full Text] [Related]
2. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE
J Med Chem; 2000 Apr; 43(7):1257-63. PubMed ID: 10753463
[TBL] [Abstract][Full Text] [Related]
3. Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Jiang W; Sui Z; Macielag MJ; Walsh SP; Fiordeliso JJ; Lanter JC; Guan J; Qiu Y; Kraft P; Bhattacharjee S; Craig E; Haynes-Johnson D; John TM; Clancy J
J Med Chem; 2003 Jan; 46(3):441-4. PubMed ID: 12540243
[TBL] [Abstract][Full Text] [Related]
4. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
[TBL] [Abstract][Full Text] [Related]
5. Pyrroloquinolone PDE5 inhibitors with improved pharmaceutical profiles for clinical studies on erectile dysfunction.
Jiang W; Guan J; Macielag MJ; Zhang S; Qiu Y; Kraft P; Bhattacharjee S; John TM; Haynes-Johnson D; Lundeen S; Sui Z
J Med Chem; 2005 Mar; 48(6):2126-33. PubMed ID: 15771456
[TBL] [Abstract][Full Text] [Related]
6. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.
Bunnage ME; Mathias JP; Wood A; Miller D; Street SD
Bioorg Med Chem Lett; 2008 Dec; 18(23):6033-6. PubMed ID: 18951784
[TBL] [Abstract][Full Text] [Related]
7. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Rosen RC; Kostis JB
Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
[TBL] [Abstract][Full Text] [Related]
8. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG
Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
[TBL] [Abstract][Full Text] [Related]
9. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
Manganiello V
Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
[No Abstract] [Full Text] [Related]
10. Sildenafil and erectile dysfunction.
Fabbri A; Aversa A; Isidori A
J Endocrinol Invest; 1999 Jun; 22(6):486-92. PubMed ID: 10435861
[No Abstract] [Full Text] [Related]
11. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
Broderick GA; Donatucci CF; Hatzichristou D; Torres LO; Valiquette L; Zhao Y; Loughney K; Sides GD; Ahuja S
J Sex Med; 2006 Jul; 3(4):668-675. PubMed ID: 16839323
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.
Seftel AD
Curr Pharm Des; 2005; 11(31):4047-58. PubMed ID: 16378510
[TBL] [Abstract][Full Text] [Related]
13. Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Sui Z; Guan J; Macielag MJ; Jiang W; Zhang S; Qiu Y; Kraft P; Bhattacharjee S; John TM; Haynes-Johnson D; Clancy J
J Med Chem; 2002 Sep; 45(19):4094-6. PubMed ID: 12213052
[TBL] [Abstract][Full Text] [Related]
14. Sildenafil in the treatment of erectile dysfunction.
Schwartz I; McCarthy D
N Engl J Med; 1998 Sep; 339(10):699-700; author reply 701-2. PubMed ID: 9729137
[No Abstract] [Full Text] [Related]
15. Sildenafil.
McMahon CG
Med J Aust; 2000 Feb; 172(4):192. PubMed ID: 10772598
[No Abstract] [Full Text] [Related]
16. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4525-32. PubMed ID: 14521414
[TBL] [Abstract][Full Text] [Related]
17. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
18. Tough choices: the cost-effectiveness of sildenafil.
McGarvey MR
Ann Intern Med; 2000 Jun; 132(12):994-5. PubMed ID: 10858184
[No Abstract] [Full Text] [Related]
19. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
[No Abstract] [Full Text] [Related]
20. Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors.
Wang Y; Chackalamannil S; Hu Z; Boyle CD; Lankin CM; Xia Y; Xu R; Asberom T; Pissarnitski D; Stamford AW; Greenlee WJ; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2002 Nov; 12(21):3149-52. PubMed ID: 12372521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
